The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hyperlipidemia drugs market was valued at US$ 21.7 Billion in 2021.
We expect the global hyperlipidemia drugs market to exhibit a CAGR of 2.17% during 2022-2027.
The rising demand for hyperlipidemia drugs to treat high cholesterol levels caused by genetic factors,
unhealthy lifestyles, and inadequate diet is primarily driving the global hyperlipidemia drugs market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for hyperlipidemia
drugs to provide safety from continuing lipid-lowering medication to the patients suffering from the
Based on the drug type, the global hyperlipidemia drugs market has been segmented into statins, bile
acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and others. Currently, statins hold
the majority of the total market share.
Based on the end user, the global hyperlipidemia drugs market can be divided into hospitals, clinics, and
others. Among these, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global hyperlipidemia drugs market include Amgen Inc., AstraZeneca
PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline
Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck &
Co. Inc., Pfizer Inc., and Sanofi S.A.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at